Cormorant Asset Management’s Abivax ABVX Stock Holding History

Cormorant Asset Management’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$90M	Sell	675,000 -85,000	-11%	-$9.62M	4.61%	9
2026 Q1	$84.6M	Sell	760,000 -590,000	-44%	-$69.8M	4.25%	8
2025 Q4	$182M	Sell	1,350,000 -600,000	-31%	-$65.5M	8.42%	3
2025 Q3	$166M	Sell	1,950,000 -180,000	-8%	-$11M	11.42%	2
2025 Q2	$16.3M	Hold	2,130,000	–	–	1.21%	20
2025 Q1	$13.3M	Hold	2,130,000	–	–	1%	24
2024 Q4	$15.6M	Hold	2,130,000	–	–	0.86%	29
2024 Q3	$24.5M	Hold	2,130,000	–	–	1.3%	24
2024 Q2	$28.2M	Hold	2,130,000	–	–	1.63%	20
2024 Q1	$30.5M	Hold	2,130,000	–	–	1.34%	23
2023 Q4	$22.8M	Buy	+2,130,000	New	+$21.7M	1.09%	27

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cormorant Asset Management's ABVX Position: Q2 2026 in Review

Cormorant Asset Management reduced its Abivax (ABVX) stake by 11% in Q2 2026, selling an estimated $9.62M and leaving 675,000 shares worth $90M. The position accounts for 4.61% of the portfolio, ranked #9.

Cormorant Asset Management first reported a position in ABVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $182M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Cormorant Asset Management held 675,000 shares of Abivax worth $90M as of Q2 2026.
Cormorant Asset Management sold 85,000 Abivax shares in Q2 2026, an estimated $9.62M.
Abivax made up 4.61% of Cormorant Asset Management's portfolio in Q2 2026, its #9 holding.
Cormorant Asset Management first reported a position in Abivax in Q4 2023 and has held it in 11 quarters since.
Cormorant Asset Management's Abivax position peaked at $182M in Q4 2025.
302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.